Akt and ERK control the proliferative response of mammary epithelial cells to the growth factors IGF-1 and EGF through the cell cycle inhibitor p57 Kip2

Science Signaling

Volumn 5, Issue 214, 2012, Pages

  Worster, Devin T ^a   Schmelzle, Tobias ^a,d   Solimini, Nicole L ^a   Lightcap, Eric S ^b   Millard, Bjorn ^a   Mills, Gordon B ^c   Brugge, Joan S ^a   Albeck, John G ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MILLENNIUM PHARMACEUTICALS INC   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1C; EPIDERMAL GROWTH FACTOR; INSULIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SOMATOMEDIN C;

ARTICLE; BREAST EPITHELIUM; CELL CYCLE; CELL PROLIFERATION; ENZYME ACTIVITY; GROWTH DISORDER; HUMAN; HUMAN CELL; MORPHOGENESIS; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; CHEMISTRY; DRUG EFFECT; MAMMARY GLAND; METABOLISM; TUMOR CELL LINE;

MAMMALIA;

CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P57; EPIDERMAL GROWTH FACTOR; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MAMMARY GLANDS, HUMAN; PROTO-ONCOGENE PROTEINS C-AKT;

EID: 84857945379     PISSN: 19450877     EISSN: 19379145     Source Type: Journal    
DOI: 10.1126/scisignal.2001986     Document Type: Article

References (60)

1. R. H. Chen, C. Sarnecki, J. Blenis, Nuclear localization and regulation of erk- and rsk-encoded protein kinases. Mol. Cell. Biol. 12, 915-927 (1992).
2. T. F. Franke, C. P. Hornik, L. Segev, G. A. Shostak, C. Sugimoto, PI3K/Akt and apoptosis: Size matters. Oncogene 22, 8983-8998 (2003).
3. B. D. Manning, Balancing Akt with S6K: Implications for both metabolic diseases and tumorigenesis. J. Cell Biol. 167, 399-403 (2004).
4. R. Sears, F. Nuckolls, E. Haura, Y. Taya, K. Tamai, J. R. Nevins, Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. Genes Dev. 14, 2501-2514 (2000).
5. A. M. Mirza, S. Gysin, N. Malek, K. Nakayama, J. M. Roberts, M. McMahon, Cooperative regulation of the cell division cycle by the protein kinases RAF and AKT. Mol. Cell. Biol. 24, 10868-10881 (2004).
6. R. J. Shaw, L. C. Cantley, Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 441, 424-430 (2006).
7. A. D. Kohn, S. A. Summers, M. J. Birnbaum, R. A. Roth, Expression of a constitutively active Akt Ser/Thr kinase in 3T3-L1 adipocytes stimulates glucose uptake and glucose transporter 4 translocation. J. Biol. Chem. 271, 31372-31378 (1996).
8. C. Rommel, B. A. Clarke, S. Zimmermann, L. Nuñez, R. Rossman, K. Reid, K. Moelling, G. D. Yancopoulos, D. J. Glass, Differentiation stage-specific inhibition of the Raf-MEK-ERK pathway by Akt. Science 286, 1738-1741 (1999).
9. S. Zimmermann, K. Moelling, Phosphorylation and regulation of Raf by Akt (protein kinase B). Science 286, 1741-1744 (1999).
10. H. Y. Irie, R. V. Pearline, D. Grueneberg, M. Hsia, P. Ravichandran, N. Kothari, S. Natesan, J. S. Brugge, Distinct roles of Akt1 and Akt2 in regulating cell migration and epithelial-mesenchymal transition. J. Cell Biol. 171, 1023-1034 (2005).
11. J. LaBaer, M. D. Garrett, L. F. Stevenson, J. M. Slingerland, C. Sandhu, H. S. Chou, A. Fattaey, E. Harlow, New functional activities for the p21 family of CDK inhibitors. Genes Dev. 11, 847-862 (1997).
12. 0 state) in fibroblasts. J. Biol. Chem. 271, 18337-18341 (1996).
13. J. Liang, J. Zubovitz, T. Petrocelli, R. Kotchetkov, M. K. Connor, K. Han, J. H. Lee, S. Ciarallo, C. Catzavelos, R. Beniston, E. Franssen, J. M. Slingerland, PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest. Nat. Med. 8, 1153-1160 (2002).
14. J. W. Harper, G. R. Adami, N. Wei, K. Keyomarsi, S. J. Elledge, The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75, 805-816 (1993).
15. W. S. el-Deiry, T. Tokino, V. E. Velculescu, D. B. Levy, R. Parsons, J. M. Trent, D. Lin, W. E. Mercer, K. W. Kinzler, B. Vogelstein, WAF1, a potential mediator of p53 tumor suppression. Cell 75, 817-825 (1993).
16. Cip1 degradation. J. Biol. Chem. 277, 9684-9689 (2002).
17. Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells. Nat. Cell Biol. 3, 245-252 (2001).
18. K. M. Pumiglia, S. J. Decker, Cell cycle arrest mediated by the MEK/mitogen-activated protein kinase pathway. Proc. Natl. Acad. Sci. U.S.A. 94, 448-452 (1997).
19. Kip2 results in increased apoptosis and delayed differentiation during mouse development. Genes Dev. 11, 973-983 (1997).
20. KIP2: "Kip"ing the cell under control. Mol. Cancer Res. 7, 1902-1919 (2009).
21. Kip2, a glucocorticoid-induced inhibitor of cell cycle progression in HeLa cells. Mol. Endocrinol. 13, 1811-1822 (1999).
22. F. Fornari, L. Gramantieri, M. Ferracin, A. Veronese, S. Sabbioni, G. A. Calin, G. L. Grazi, C. Giovannini, C. M. Croce, L. Bolondi, M. Negrini, MiR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma. Oncogene 27, 5651-5661 (2008).
23. J. W. Kim, S. Mori, J. R. Nevins, Myc-induced microRNAs integrate Myc-mediated cell proliferation and cell fate. Cancer Res. 70, 4820-4828 (2010).
24. K. Buchkovich, L. A. Duffy, E. Harlow, The retinoblastoma protein is phosphorylated during specific phases of the cell cycle. Cell 58, 1097-1105 (1989).
25. G. G. Freund, D. T. Kulas, R. A. Mooney, Insulin and IGF-1 increase mitogenesis and glucose metabolism in the multiple myeloma cell line, RPMI 8226. J. Immunol. 151, 1811-1820 (1993).
26. K. Hayashi, M. Takahashi, K. Kimura, W. Nishida, H. Saga, K. Sobue, Changes in the balance of phosphoinositide 3-kinase/protein kinase B (Akt) and the mitogen-activated protein kinases (ERK/p38MAPK) determine a phenotype of visceral and vascular smooth muscle cells. J. Cell Biol. 145, 727-740 (1999).
27. B. Karakas, A. Weeraratna, A. Abukhdeir, B. G. Blair, H. Konishi, S. Arena, K. Becker, W. Wood III, P. Argani, A. M. De Marzo, K. E. Bachman, B. H. Park, Interleukin-1 alpha mediates the growth proliferative effects of transforming growth factor-beta in p21 null MCF-10A human mammary epithelial cells. Oncogene 25, 5561-5569 (2006).
28. A. D. Kohn, A. Barthel, K. S. Kovacina, A. Boge, B. Wallach, S. A. Summers, M. J. Birnbaum, P. H. Scott, J. C. Lawrence Jr., R. A. Roth, Construction and characterization of a conditionally active version of the serine/threonine kinase Akt. J. Biol. Chem. 273, 11937-11943 (1998).
29. I. Amit, A. Citri, T. Shay, Y. Lu, M. Katz, F. Zhang, G. Tarcic, D. Siwak, J. Lahad, J. Jacob-Hirsch, N. Amariglio, N. Vaisman, E. Segal, G. Rechavi, U. Alon, G. B. Mills, E. Domany, Y. Yarden, A module of negative feedback regulators defines growth factor signaling. Nat. Genet. 39, 503-512 (2007).
30. L. V. Sharova, A. A. Sharov, T. Nedorezov, Y. Piao, N. Shaik, M. S. Ko, Database for mRNA half-life of 19 977 genes obtained by DNA microarray analysis of pluripotent and differentiating mouse embryonic stem cells. DNA Res. 16, 45-58 (2009).
31. J. Guo, J. Cai, L. Yu, H. Tang, C. Chen, Z. Wang, EZH2 regulates expression of p57 and contributes to progression of ovarian cancer in vitro and in vivo. Cancer Sci. 102, 530-539 (2011).
32. R. M. Neve, K. Chin, J. Fridlyand, J. Yeh, F. L. Baehner, T. Fevr, L. Clark, N. Bayani, J. P. Coppe, F. Tong, T. Speed, P. T. Spellman, S. DeVries, A. Lapuk, N. J. Wang, W. L. Kuo, J. L. Stilwell, D. Pinkel, D. G. Albertson, F. M. Waldman, F. McCormick, R. B. Dickson, M. D. Johnson, M. Lippman, S. Ethier, A. Gazdar, J. W. Gray, A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 10, 515-527 (2006).
33. J. P. Gustin, B. Karakas, M. B. Weiss, A. M. Abukhdeir, J. Lauring, J. P. Garay, D. Cosgrove, A. Tamaki, H. Konishi, Y. Konishi, M. Mohseni, G. Wang, D. M. Rosen, S. R. Denmeade, M. J. Higgins, M. I. Vitolo, K. E. Bachman, B. H. Park, Knockin of mutant PIK3CA activates multiple oncogenic pathways. Proc. Natl. Acad. Sci. U.S.A. 106, 2835-2840 (2009).
34. J. Debnath, K. R. Mills, N. L. Collins, M. J. Reginato, S. K. Muthuswamy, J. S. Brugge, The role of apoptosis in creating and maintaining luminal space within normal and oncogene-expressing mammary acini. Cell 111, 29-40 (2002).
35. R. C. Muise-Helmericks, H. L. Grimes, A. Bellacosa, S. E. Malstrom, P. N. Tsichlis, N. Rosen, Cyclin D expression is controlled post-transcriptionally via a phosphatidylinositol 3-kinase/Akt-dependent pathway. J. Biol. Chem. 273, 29864-29872 (1998).
36. 1 phase. Biochem. J. 326 (Pt. 1), 61-68 (1997).
37. L. Ma, Z. Chen, H. Erdjument-Bromage, P. Tempst, P. P. Pandolfi, Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis. Cell 121, 179-193 (2005).
38. B. D. Manning, A. R. Tee, M. N. Logsdon, J. Blenis, L. C. Cantley, Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/Akt pathway. Mol. Cell 10, 151-162 (2002).
39. C. C. Wang, I. Gurevich, B. Draznin, Insulin affects vascular smooth muscle cell phenotype and migration via distinct signaling pathways. Diabetes 52, 2562-2569 (2003).
40. F. L. Vaughan, L. L. Kass, J. A. Uzman, Requirement of hydrocortisone and insulin for extended proliferation and passage of rat keratinocytes. In Vitro 17, 941-946 (1981).
41. T. G. Ram, K. E. Kokeny, C. A. Dilts, S. P. Ethier, Mitogenic activity of neu differentiation factor/heregulin mimics that of epidermal growth factor and insulin-like growth factor-I in human mammary epithelial cells. J. Cell. Physiol. 163, 589-596 (1995).
42. 1 blocked cells of hypophysectomized animals. Science 208, 410-412 (1980).
43. M. E. Mattsson, G. Enberg, A. I. Ruusala, K. Hall, S. Pahlman, Mitogenic response of human SH-SY5Y neuroblastoma cells to insulin-like growth factor I and II is dependent on the stage of differentiation. J. Cell Biol. 102, 1949-1954 (1986).
44. KIP2, a cyclin-dependent kinase inhibitor, in mouse. Nat. Genet. 11, 204-206 (1995).
45. KIP2 gene at 11p15.5. Oncogene 12, 1365-1368 (1996).
46. KIP2, on chromosome 11p15. Proc. Natl. Acad. Sci. U.S.A. 93, 3026-3030 (1996).
47. E. Halilovic, Q. B. She, Q. Ye, R. Pagliarini, W. R. Sellers, D. B. Solit, N. Rosen, PIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK/ERK and mutant KRAS signaling. Cancer Res. 70, 6804-6814 (2010).
48. kip2 is a candidate tumor suppressor gene in human breast cancer. BMC Cancer 8, 68 (2008).
49. B. A. Rodriguez, Y. I. Weng, T. M. Liu, T. Zuo, P. Y. Hsu, C. H. Lin, A. L. Cheng, H. Cui, P. S. Yan, T. H. Huang, Estrogen-mediated epigenetic repression of the imprinted gene cyclin-dependent kinase inhibitor 1C in breast cancer cells. Carcinogenesis 32, 812-821 (2011).
50. KIP2) is a direct target of EZH2 and suppressed by multiple epigenetic mechanisms in breast cancer cells. PLoS One 4, e5011 (2009).
51. KIP2expression and loss of heterozygosity during immortal conversion of cultured human mammary epithelial cells. Cancer Res. 59, 5112-5118 (1999).
52. S. Fujii, K. Tokita, N. Wada, K. Ito, C. Yamauchi, Y. Ito, A. Ochiai, MEK-ERK pathway regulates EZH2 overexpression in association with aggressive breast cancer subtypes. Oncogene 30, 4118-4128 (2011).
53. T. L. Cha, B. P. Zhou, W. Xia, Y. Wu, C. C. Yang, C. T. Chen, B. Ping, A. P. Otte, M. C. Hung, Akt-mediated phosphorylation of EZH2 suppresses methylation of lysine 27 in histone H3. Science 310, 306-310 (2005).
54. N. Borisov, E. Aksamitiene, A. Kiyatkin, S. Legewie, J. Berkhout, T. Maiwald, N. P. Kaimachnikov, J. Timmer, J. B. Hoek, B. N. Kholodenko, Systems-level interactions between insulin-EGF networks amplify mitogenic signaling. Mol. Syst. Biol. 5, 256 (2009).
55. W. W. Chen, B. Schoeberl, P. J. Jasper, M. Niepel, U. B. Nielsen, D. A. Lauffenburger, P. K. Sorger, Input-output behavior of ErbB signaling pathways as revealed by a mass action model trained against dynamic data. Mol. Syst. Biol. 5, 239 (2009).
56. K. A. Janes, C. C. Wang, K. J. Holmberg, K. Cabral, J. S. Brugge, Identifying single-cell molecular programs by stochastic profiling. Nat. Methods 7, 311-317 (2010).
57. M. J. Reginato, K. R. Mills, J. K. Paulus, D. K. Lynch, D. C. Sgroi, J. Debnath, S. K. Muthuswamy, J. S. Brugge, Integrins and EGFR coordinately regulate the pro-apoptotic protein Bim to prevent anoikis. Nat. Cell Biol. 5, 733-740 (2003).
58. M. R. Lamprecht, D. M. Sabatini, A. E. Carpenter, CellProfiler: Free, versatile software for automated biological image analysis. Biotechniques 42, 71-75 (2007).
59. B. L. Millard, M. Niepel, M. P. Menden, J. L. Muhlich, P. K. Sorger, Adaptive informatics for multifactorial and high-content biological data. Nat. Methods 8, 487-493 (2011).
60. T. Schmelzle, A. A. Mailleux, M. Overholtzer, J. S. Carroll, N. L. Solimini, E. S. Lightcap, O. P. Veiby, J. S. Brugge, Functional role and oncogene-regulated expression of the BH3-only factor Bmf in mammary epithelial anoikis and morphogenesis. Proc. Natl. Acad. Sci. U.S.A. 104, 3787-3792 (2007).